GSK warns of lower 2024 vaccine sales on weaker demand
GSK said today its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, sending its shares 4% lower in early trade.
Business
• 30 Oct 24
